Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 104   

Articles published

NVS 88.95 +0.35 (0.40%)
price chart
Novartis Takes Stake In Gamida Cell With Option To Acquire
Novartis AG (ADR) (NVS) has signed an agreement with Gamida Cell to invest $35 million in the Israel-based stem cell biotech company.
Related articles »  
Novartis, Global Alliance Collaborate To Search For TB Cure
Switzerland-based Novartis AG (ADR) (NVS) signed a deal today to license its experimental drugs for the treatment of tuberculosis (TB) to the Global Alliance for TB Drug Development (TB Alliance).
Related articles »  
Hospira Granted Restraining Order Against FDA Approval Of Generics
Novartis AG's (ADR) (NVS) unit Sandoz backed Hospira's stance; Sandoz and Hospira had reached a settlement over patent disputes earlier this year.
Related articles »  
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
Novartis' second quarter results were disappointing. Core earnings per share came in at $1.34, up 7% from the year-ago period but missed the Zacks Consensus Estimate of $1.36.
Related articles »  
Safest Dividend Stocks In The Market
Novartis is a perfect selection because it has a slew of pharmaceutical products and always is on the hunt for new ones. Like Merck, that means consistent and reliable cash flow, which means consistent and reliable dividends.
Novartis' New Heart Drug Expected To Be A Hit
Novartis AG (ADR) (NVS) announced today that it will showcase its heart failure drug LCZ696 on August 31 at the annual meeting of the European Society of Cardiology (ESC).
Related articles »  
Active Movers - Novartis AG (ADR) (NYSE:NVS), Alkermes Plc (NASDAQ:ALKS ...
Manhattan, NY- 16 AUG, 2014 - (Techsonian) - Novartis AG (ADR) (NYSE:NVS)released thatBiotechnology stocks were among the top performers in 2012 and 2013.
Novartis To Offer Stiff Competition To Amgen's Neupogen
Novartis AG (ADR) (NVS) announced yesterday that the Food and Drug Administration (FDA) had accepted the Biologics License Application for filgrastim by Sandoz - the generics arm of Novartis.
Related articles »  
Biotech Stocks With Unique Diagnostic and Therapeutic Technologies [Novartis ...
For example, Genentech/Roche Holding AG's (RHHBY:OTCQX) Herceptin is almost a $7 billion ($7B) global franchise, but only 20-30% of all breast cancer patients are positive for HER2 (human epidermal growth factor receptor 2), and will respond to the ...
Related articles »  
Novartis AG (ADR) (NYSE:NVS) Considering To Challenge European ...
Dallas, Texas 07/28/2014 (ustradevoice) - Novartis AG (ADR) (NYSE:NVS) on July 25, 2014 announced that it was considering to challenge the decision of Italian and French Governments for violation of European Union regulatory framework.
Related articles »